Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?

Liver Int. 2022 Dec;42(12):2597-2598. doi: 10.1111/liv.15434.

Wei-Yu Kao^{1

2

3

4}, Chien-Wei Su^{5

6

7

8}

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
² Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
³ Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan.
⁴ TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei, Taiwan.
⁵ Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
⁶ Department of Internal Medicine, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁷ Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁸ Hospitalist Ward, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

No abstract available

Publication types